|Bid||46.00 x 1000|
|Ask||48.30 x 400|
|Day's Range||46.85 - 48.32|
|52 Week Range||41.31 - 99.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.67|
Clovis Oncology, Inc. will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding CLVS totaled $2.36 billion.
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on CLVS sign up now at www.wallstequities.com/registration. On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories.
BOULDER, Colo.-- -- The filing is based on positive phase 3 ARIEL3 clinical trial data in which rucaparib significantly improved progression free survival compared to placebo in all primary efficacy ovarian cancer patient populations Timing of validation by EMA may allow for a CHMP opinion on maintenance treatment by year-end 2018 Clovis Oncology, Inc. today announced that the European Medicines Agency ...
NEW YORK, NY / ACCESSWIRE / July 4, 2018 / U.S. equities dropped on Tuesday, as gains in energy, real-estate and telecom shares were offset by losses in tech and financial names. The Dow Jones Industrial ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PBF ...
NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...
NEW YORK, NY / ACCESSWIRE / June 14, 2018 / U.S. markets fell Wednesday after the Federal Reserve raised interest rates and hinted at more increases were coming in 2018. The Dow Jones Industrial Average ...
Clovis Oncology, Inc. today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 4:00 PM Pacific Time.
Clovis Oncology (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunomedics popped to an 18-year high Monday after it unveiled plans for its cancer drug, including a tie-up with Clovis Oncology to test a regimen.
Clovis Oncology, Inc. today announced the submission of a regulatory application to the European Medicines Agency , as part of a type II variation seeking to expand the marketing authorization for Rubraca to include maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy....
Companies to Start Phase 1/ 2 Study to Evaluate the Combination of Rubraca ® and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer. BOULDER, ...
Clovis Oncology's (CLVS) PARP inhibitor, Rubraca, gets its first approval in Europe for the treatment of BRCA-mutant ovarian cancer in third- or later-line setting.
Clovis Oncology, Inc. (CLVS) today announced that the European Commission (EC) has authorized Rubraca (rucaparib) as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. Certain confirmatory post-marketing commitments are required as part of this conditional authorization.
In the first quarter, Clovis Oncology’s (CLVS) operating expenses rose YoY (year-over-year) to $100.6 million from $80.4 million, due to a larger net loss and inventories rising. Clovis’s investments fell YoY to $9.8 million from $86.6 million due to the company buying $133 million in available-for-sale securities and selling $50 million in securities in 2017. In the first quarter of this year, Clovis sold $10 million in available-for-sale securities and purchased $217,000 in property and equipment. Clovis generated $226.9 million from financing activities in the first quarter of 2017.
Clovis Oncology’s (CLVS) ARIEL4 study on ovarian cancer is currently open for enrolment. The Phase 3 multicenter randomized study is focusing on Rubraca (rucaparib) in relapsed ovarian cancer patients whose cancer has advanced after two or more lines of therapy. The primary endpoint of this trial is progression-free survival. In collaboration with Bristol-Myers Squibb, Clovis is also sponsoring and conducting ATHENA, a study on first-line maintenance treatment of advanced ovarian cancer.
In the first quarter, Clovis Oncology’s (CLVS) product revenue rose YoY (year-over-year) to $18.5 million from $7 million. This revenue primarily consisted of US Rubraca (rucaparib) sales.
Clovis Oncology (CLVS) is a biopharmaceutical company with a focus on acquiring, developing, and commercializing anti-cancer agents. Clovis’s Rubraca (rucaparib), launched in the United States in December 2016, is approved for treating adult patients with deleterious BRCA1-mutation epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapies. Of the nine analysts covering Clovis Oncology, seven have recommended “buy” or a higher rating, while two have recommended “hold.” Clovis’s target price of $79.57 implies a 67.4% upside based on the stock’s May 24 closing price of $47.52.
The FDA’s approval of Clovis Oncology’s (CLVS) Rubraca (rucaparib) for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in April was the second and much broader indication the drug has been approved for. Unlike for its first indication, diagnostic testing is not required for patients to be prescribed Rubraca for this maintenance indication. In March, the EMA’s (European Medicines Agency) committee for medicinal products gave a positive opinion on granting conditional marketing authorization for Rubraca as a monotherapy for adult patients with relapsed and platinum-sensitive BRCA1-mutated high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more platinum-based chemotherapies and are unable to tolerate more.
Clovis Oncology, Inc. today announced that seven abstracts highlighting progress in the Rubraca preclinical research and clinical development program will be presented at the 2018 American Society of Clinical Oncology Annual Meeting taking place June 1-5 in Chicago.